Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4407-4412

  Eisterer, Wolfgang ^a   De Vries, Alexander ^b   Kendler, Dorota ^a   Spechtenhauser, Bernhard ^c   Königsrainer, Alfred ^d   Nehoda, Hermann ^a,e   Virgolini, Irene ^a   Lukas, Peter ^a   Bechter, Oliver ^a   Wöll, Ewald ^f   Öfner, Dietmar ^g  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b General Hospital Feldkirch   (Austria)

^c General Hospital Kufstein   (Austria)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e St Johann General Hospital   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Cisplatin; Docetaxel; Esophageal cancer; Neoadjuvant therapy; Phase II trials; Radiochemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERTENSION; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DRUG THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RADIOTHERAPY; REMISSION INDUCTION; TAXOIDS; TREATMENT OUTCOME;

EID: 84855170323     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Blot WJ and McLaughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 26: 2-8, 1999. (Pubitemid 29529530)
2. Salazar JD, Doty JR, Lin JW, Dyke MC, Roberts J, Heitmiller ES and Heitmiller RF: Does cell type influence post-esophagectomy survival in patients with esophageal cancer? Dis Esophagus 11: 168-171, 1998. (Pubitemid 28515546)
3. Gebski V, Burmeister B, Smithers BM, Foo Z, Zalcberg J, Simes J, for the Australasian Gastro-Intestinal Group: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in esophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234, 2007. (Pubitemid 46291702)
4. Herskovic A, Martz K, Al-Sarraf M, Leichmann L, Brindle J, Vaitkevicius VK, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598, 1992.
5. Al-Sarraf M, Martz K, Herskovic A, leichmann L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L and Emami B: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15: 277-284, 1997. (Pubitemid 27020584)
6. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, for the Australasian Gastro-Intestinal Group: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12: 681-692, 2011.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24: 4991-4997, 2006. (Pubitemid 46631401)
8. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Consetnla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E; V-325 Study Group: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25: 3205-3209, 2007. (Pubitemid 47333732)
9. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C and Lordick F: Split-dose doectaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18: 1673-1679, 2007. (Pubitemid 47506254)
10. Lorenzen S, Duyster J, Lersch C, von Delius S, Henning M, Bredenkamp R, Peschel C and Lordick F: Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 92: 2129-2133, 2005. (Pubitemid 40966246)
11. Mauer AM, Masters GA, Haraf DJ, Hoffmann PC, Watson SM, Golomb HM and Vokes EE: Phase I study of Docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16: 159-164, 1998. (Pubitemid 28041594)
12. Mauer AM, Haraf DC, Ferguson MK, Posner MC, Sandler A, Kessler K, Hoffman PC, Rudin CM, Talabay K and Vokes EE: Docetaxel-based combined modality therapy for locally advanced carcinoma of the esophagus and gastric cardia. Proc Am Soc Clin Oncol 19: 246a (abstr.), 2000.
13. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD and Roth JA: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92: 279-286, 2001. (Pubitemid 32664433)
14. Sobin LH, Hermanek P and Hutter RV: TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer 61: 2310-2314, 1988.
15. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 2.0. published: 30th April 1999. US Department of Health and Human Services, National Institute of Health, National Cancer Institute.
16. Therasse P, Eisenhauer EA and Verweij J: RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42: 1031-1039, 2006.
17. Gehan E. The determination of the numbers of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13: 346-353, 1961.
18. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Medicine 355: 11-20, 2006.
19. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P and Rougier P: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter Phase III trial. J Clin Oncol 29: 1715-1721, 2011.
20. Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F, Bonomo G, Crosta C, Huber O: Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 16: 868-874, 2010.
21. Van Cutsem E, Van de Velde C, Roth A, Lordick F, Könne C-H, Cascinu S and Aapro M: Expert opinion on management of gastric and gastro-esophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - Gastrointestinal Cancer Group. Eur J Cancer 44: 182-194, 2008.
22. Balcer-Kubiczek EK, Attarpour M, Jiang J, Kennedy AS and Suntharalingam M: Cytotoxicity of docetaxel (Taxotere) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells. Chemotherapy 52: 231-240, 2006. (Pubitemid 44284919)
23. Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, BalmerMajno S, Köberle D, Terraciano L, Schnider A, Bodis S and Popescu R for the Swiss Group for Clinical Cancer Research (SAKK): Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02) Ann Oncol 20: 1522-1528, 2009.
24. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M and Siewert JR: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24: 4692-4698, 2006. (Pubitemid 46646244)
25. Kendler D, Gabriel M, Uprimny C, Eisterer W and Virgolini I. The value of 18FDG-PET for staging and therapy monitoring in patients with esophageal cancer. Eur J Nucl Med Mol Imaging 33: 259, 2006.